181 related articles for article (PubMed ID: 17379472)
21. Quality of care in patients with chronic hepatitis C virus infection: a cohort study.
Kanwal F; Schnitzler MS; Bacon BR; Hoang T; Buchanan PM; Asch SM
Ann Intern Med; 2010 Aug; 153(4):231-9. PubMed ID: 20713791
[TBL] [Abstract][Full Text] [Related]
22. Understanding hepatitis B, hepatitis C and HIV among people who inject drugs in South Africa: findings from a three-city cross-sectional survey.
Scheibe A; Young K; Moses L; Basson RL; Versfeld A; Spearman CW; Sonderup MW; Prabdial-Sing N; Manamela J; Puren AJ; Rebe K; Hausler H
Harm Reduct J; 2019 Apr; 16(1):28. PubMed ID: 30975139
[TBL] [Abstract][Full Text] [Related]
23. HEPACOM: multicenter, observational prospective study of outcome and monitoring of HCV positive antiviral-naïve patients managed in the French health care system.
Agostini H; Castera L; Melin P; Cattan L; Roudot-Thoraval F
Gastroenterol Clin Biol; 2007 Dec; 31(12):1074-80. PubMed ID: 18176360
[TBL] [Abstract][Full Text] [Related]
24. Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users.
Edlin BR; Kresina TF; Raymond DB; Carden MR; Gourevitch MN; Rich JD; Cheever LW; Cargill VA
Clin Infect Dis; 2005 Apr; 40 Suppl 5(Suppl 5):S276-85. PubMed ID: 15768335
[TBL] [Abstract][Full Text] [Related]
25. Hepatitis C virus infection: prevalence, predictor variables and prevention opportunities among drug users in Italy.
Quaglio GL; Lugoboni F; Pajusco B; Sarti M; Talamini G; Mezzelani P; Des Jarlais DC;
J Viral Hepat; 2003 Sep; 10(5):394-400. PubMed ID: 12969192
[TBL] [Abstract][Full Text] [Related]
26. Introducing hepatitis C virus healthcare pathways in addiction care in the Netherlands with a Breakthrough project: a mixed method study.
Kracht PAM; de Gee EA; van der Poel A; Verhagen MAMT; Hoepelman AIM; Croes EA; Arends JE
Harm Reduct J; 2019 Jul; 16(1):45. PubMed ID: 31307470
[TBL] [Abstract][Full Text] [Related]
27. Change in treatment paradigm in people who previously injected drugs with chronic hepatitis C in the era of direct-acting antiviral therapy.
Wong GL; Chan HL; Loo CK; Hui YT; Fung JY; Cheung D; Chung C; Chim AM; Wong VW;
J Gastroenterol Hepatol; 2019 Sep; 34(9):1641-1647. PubMed ID: 30707777
[TBL] [Abstract][Full Text] [Related]
28. Integrated models of care for people who inject drugs and live with hepatitis C virus: A systematic review.
Socías ME; Karamouzian M; Parent S; Barletta J; Bird K; Ti L
Int J Drug Policy; 2019 Oct; 72():146-159. PubMed ID: 31147142
[TBL] [Abstract][Full Text] [Related]
29. Hepatitis C virus control among persons who inject drugs requires overcoming barriers to care.
Zeremski M; Zibbell JE; Martinez AD; Kritz S; Smith BD; Talal AH
World J Gastroenterol; 2013 Nov; 19(44):7846-51. PubMed ID: 24307778
[TBL] [Abstract][Full Text] [Related]
30. Hepatitis C treatment of opioid dependants receiving maintenance treatment: results of a Norwegian pilot study.
Krook AL; Stokka D; Heger B; Nygaard E
Eur Addict Res; 2007; 13(4):216-21. PubMed ID: 17851243
[TBL] [Abstract][Full Text] [Related]
31. Management of hepatitis C among drug users attending general practice in Ireland: baseline data from the Dublin area hepatitis C in general practice initiative.
Cullen W; Stanley J; Langton D; Kelly Y; Bury G
Eur J Gen Pract; 2007; 13(1):5-12. PubMed ID: 17366287
[TBL] [Abstract][Full Text] [Related]
32. NIH Consensus Statement on Management of Hepatitis C: 2002.
NIH Consens State Sci Statements; 2002 Jun 10-12; 19(3):1-46. PubMed ID: 14768714
[TBL] [Abstract][Full Text] [Related]
33. Identifying Barriers to the Treatment of Chronic Hepatitis C Infection.
Al-Khazraji A; Patel I; Saleh M; Ashraf A; Lieber J; Malik R
Dig Dis; 2020; 38(1):46-52. PubMed ID: 31422405
[TBL] [Abstract][Full Text] [Related]
34. Outpatient drug treatment program directors' hepatitis C-related beliefs and their relationship to the provision of HCV services.
Astone JM; Strauss SM; Hagan H; Des Jarlais DC
Am J Drug Alcohol Abuse; 2004 Nov; 30(4):783-97. PubMed ID: 15624549
[TBL] [Abstract][Full Text] [Related]
35. Changes to the national strategies, plans and guidelines for the treatment of hepatitis C in people who inject drugs between 2013 and 2016: a cross-sectional survey of 34 European countries.
Maticic M; Zorman JV; Gregorcic S; Schatz E; Lazarus JV
Harm Reduct J; 2019 May; 16(1):32. PubMed ID: 31072401
[TBL] [Abstract][Full Text] [Related]
36. Time to rethink antiviral treatment for hepatitis C in patients with coexisting mental health/substance abuse issues.
Bonner JE; Barritt AS; Fried MW; Evon DM
Dig Dis Sci; 2012 Jun; 57(6):1469-74. PubMed ID: 22484494
[TBL] [Abstract][Full Text] [Related]
37. Assessing Racial Disparities in HCV Infection and Care Outcomes in a Southern Urban Population.
McGonigle K; Carley T; Hoff C
J Racial Ethn Health Disparities; 2018 Oct; 5(5):1052-1058. PubMed ID: 29288470
[TBL] [Abstract][Full Text] [Related]
38. [Treatment of chronic hepatitis C within a heroine-assisted treatment program].
Deibler P; Haasen C; Reimer J
Dtsch Med Wochenschr; 2006 Dec; 131(50):2835-7. PubMed ID: 17160765
[TBL] [Abstract][Full Text] [Related]
39. Appendix: The National Institutes of Health Consensus Development Conference Management of Hepatitis C 2002.
Seeff LB; Hoofnagle JH
Clin Liver Dis; 2003 Feb; 7(1):261-87. PubMed ID: 12691470
[TBL] [Abstract][Full Text] [Related]
40. Treatment access is only the first step to hepatitis C elimination: experience of universal anti-viral treatment access in Australia.
Doyle JS; Scott N; Sacks-Davis R; Pedrana AE; Thompson AJ; Hellard ME;
Aliment Pharmacol Ther; 2019 May; 49(9):1223-1229. PubMed ID: 30908706
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
